|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||54.75 - 55.43|
|52 Week Range||54.40 - 66.80|
|PE Ratio (TTM)||29.89|
|Forward Dividend & Yield||1.88 (3.41%)|
|1y Target Est||N/A|
Cancer immunotherapies and targeted therapies offer renewed hope to lung-cancer patients.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Merck & Co., Inc. Here are 5 ETFs with the largest exposure to MRK-US. Comparing the performance and risk of Merck & Co., Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Merck & Co., Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Merck & Co., Inc. – Pfizer Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ADR, ... Read more (Read more...)
New CEO Joe Papa has done a nice job in his efforts to turn around Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Generic drugmakers have been taken to the woodshed, with Teva Pharmaceutical Industries Ltd (NYSE:TEVA) down 67% year-to-date and Mallinckrodt PLC (NYSE:MNK) off 56%.
Johnson & Johnson (JNJ) puts forth positive data from CANVAS study on its type II diabetes drug, Invokana, showing better renal outcomes.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is continuing the slow, painful process of unwinding from its debt and becoming a regular drug company.
Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.
CHMP has given a positive opinion recommending the marketing approval of Merck's (MRK) Prevymis for the prevention of CMV infection.
President Donald Trump on Monday said he is nominating former pharmaceutical executive and industry lobbyist Alex Azar to serve as U.S. Health and Human Services secretary, saying Azar would push to lower the price of medicines. Republicans as well as the lead lobby groups for drugmakers and health insurers welcomed Azar as an experienced hand who could help overhaul the world's most costly healthcare system.
Merck & Co Inc’s (NYSE:MRK) most recent return on equity was a substandard 6.96% relative to its industry performance of 16.15% over the past year. An investor may attribute anRead More...
The October 31 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks decreased.
Key highlights this week include AstraZeneca's (AZN) Q3 results and the FDA approval of the first new CMV medicine in 15 years.
TRENTON, N.J. (AP) — In a story Nov. 8 about a new drug approval, The Associated Press misspelled the drug's name. It is Prevymis, not Prevymix.
Merck & Co Ltd's drug to prevent serious infection in patients who undergo a type of stem cell transplant was approved by the U.S. Food and Drug Administration, the drugmaker said on Thursday. Merck said the drug, which is expected to be available from December, was approved both as a tablet and an injection. The list price for the tablets is $195 per day, while it is $270 a day for the injection.
AstraZeneca's (AZN.L) drug sales fell again in the third quarter, hit by generic competition to former blockbusters like cholesterol pill Crestor, although the pace of decline slowed as it looks to new cancer treatments to revive its fortunes. Product sales were down 3 percent compared with an 11 percent fall during the first half of the year. Chief Executive Pascal Soriot believes the drugmaker has reached a turning-point as its pipeline of new medicines starts to deliver and the impact of patent losses recedes.
By Ludwig Burger FRANKFURT (Reuters) - Germany's Merck KGaA (MRCG.DE) said it was targeting the lower end of its forecast ranges for 2017 results after a stronger euro inflated costs, though double-digit ...
AstraZeneca's drug sales fell 3 percent in the third quarter, hit again by generic competition to former blockbusters like cholesterol pill Crestor, as it looks to new cancer treatments to revive its fortunes. ...
Keytruda just wasn't strong enough to overcome stiff headwinds that made Merck's third-quarter report one investors would like to forget.
Nov.09 -- Merck Kgaa CFO Marcus Kuhnert discusses the company's earnings and performance. He speaks on "Bloomberg Markets."
Keith Bliss of Cuttone and Company joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss the current dealmaking environment on Wall Street, as M&A and IPO activity heat up. Is it the sign of a market top, as some analysts are warning?